Skip to main content

Production and Purification of Recombinant Proteins

  • 111k Accesses

Abstract

The growing demand for therapeutic proteins, especially monoclonal antibodies, increases the need for practical and economical processing techniques. Such techniques evolved rapidly over the last few decades. In this chapter an overview is given of the main biotechnological production systems with a focus on mammalian cultures and a brief description of prokaryotic cell systems, transgenic technology and plant cells, and of the main purification systems with a focus on technologies such as filtration, centrifugation, precipitation and chromatography. The critical quality attribute concept of biopharmaceuticals is discussed and its relation to the concept of quality by design, as well as strategies to decrease the cost of goods and increase process robustness to ensure consistent and safe production of biopharmaceuticals within large scale manufacturing plants.

Keywords

  • Recombinant proteins
  • Production
  • Purification
  • Quality
  • Efficiency
  • Downstream processing
  • Upstream processing

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-00710-2_4
  • Chapter length: 26 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   89.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-00710-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   119.99
Price excludes VAT (USA)
Figure 4.1
Figure 4.2
Figure 4.3
Figure 4.4
Figure 4.5
Figure 4.6
Figure 4.7
Figure 4.8
Figure 4.9

References

  • Abi-Ghanem DA, Berghman LR (2012) Immunoaffinity chromatography: a review. http://cdn.intechopen.com/pdfs-wm/33050.pdf

  • Afeyan N, Gordon N, Mazsaroff I, Varady L, Fulton S, Yang Y, Regnier F (1989) Flow-through particles of the high-performance liquid chromatographic separation of biomolecules, perfusion chromatography. J Chromatogr 519:1–29

    CrossRef  Google Scholar 

  • Berridge J, Seamon K, Venugopal S (2009) A-Mab: a case study in BioProcess development, version 2.1, 30th October 2009. http://c.ymcdn.com/sites/www.casss.org/resource/resmgr/imported/A-Mab_Case_Study_Version_2-1.pdf

  • Berthold W, Walter J (1994) Protein purification: aspects of processes for pharmaceutical products. Biologicals 22:135–150

    CAS  CrossRef  Google Scholar 

  • BioPhorum Operations Group (2017) Biomanufacturing technology roadmap. www.biophorum.com/wp-content/uploads/2017/07/SupplyPartMgmnt.pdf

  • Cartwright T (1987) Isolation and purification of products from animal cells. Trends Biotechnol 5:25–30

    CAS  CrossRef  Google Scholar 

  • Celik E, Calik P (2012) Production of recombinant proteins by yeast cells. Biotechnol Adv 30(5):1108–1118

    CAS  CrossRef  Google Scholar 

  • Chase H, Draeger N (1993) Affinity purification of proteins using expanded beds. J Chromatogr 597:129–145

    CrossRef  Google Scholar 

  • Chase HA (1994) Purification of proteins by adsorption chromatography in expanded beds. Trends Biotechnol 12:296–303

    CAS  CrossRef  Google Scholar 

  • Chen T, Zhang K, Gruenhagen J, Medley CD (2015) Hydrophobic interaction chromatography for antibody drug conjugate drug distribution analysis. american pharmaceutical review. www.americanpharmaceuticalreview.com/Featured-Articles/177927

  • Compton B, Jensen J (2007) Use of perfusion technology on the Rise – New modes are beginning to gain ground on Fed-Batch strategy. Genet Eng Biotechnol News 27:48

    Google Scholar 

  • Council of Europe (2011) Cell substrates for the production of vaccines for human use. In: European Pharmacopoeia, 7th edn. Council of Europe, Strasbourg

    Google Scholar 

  • Cumming DA (1991) Glycosylation of recombinant protein therapeutics: Control and functional implications. Glycobiology 1:115–130

    CAS  CrossRef  Google Scholar 

  • Dell A, Galadari A, Sastre F, Hitchen P (2011) Similarities and differences in the glycosylation mechanisms in prokaryotes and eukaryotes. Int J Microbiol 2010:148178

    PubMed Central  Google Scholar 

  • Dos Santos NV, De Carvalho Santos-Ebinuma V, Pessoa A Jr, Brandao Pereira JF (2018) Liquid-liquid extraction of biopharmaceuticals from fermented broth: trends and future prospects. J Chem Technol Biotechnol 93(7):1845–1863

    CAS  CrossRef  Google Scholar 

  • Eibl R, Eibl D (eds) (2011) Single-use technology in biopharmaceuticalmanufacture. Wiley, Hoboken

    Google Scholar 

  • EMA (2011) Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3)

    Google Scholar 

  • Etzel MR, Arunkumar A (2017) Charged ultrafiltration and microfiltration membranes for antibody purification. In: Gottschalk U (ed) Process scale purification of antibodies. Wiley, Hoboken. https://doi.org/10.1002/9781119126942.ch12

    CrossRef  Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMA) (1996) Note for guidance for virus validation studies: design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95)

    Google Scholar 

  • FDA, Center for Biologics Evaluation and Research (1990) Cytokine and growth factor pre-pivotal trial information package with special emphasis on products identified for consideration under 21 CFR 312 Subpart E. FDA, Bethesda

    Google Scholar 

  • FDA, Office of Biologicals Research and Review (1993) Points to consider in the characterization of cell lines used to produce biologicals. FDA, Rockville Pike

    Google Scholar 

  • Fulton SP (1994) Large scale processing of macromolecules. Curr Opin Biotechnol 5:201–205

    CAS  CrossRef  Google Scholar 

  • Goldstein A, Molina O (2016) Implementation strategies and challenges: single use technologies. PepTalk Presentation

    Google Scholar 

  • Gottschalk U (2006) The renaissance of protein purification. BioPharm Int 19:S8–S9

    Google Scholar 

  • Groves MJ (1988) Parenteral technology manual: an introduction to formulation and production aspects of parenteral products. Interpharm Press, Buffalo Grove

    Google Scholar 

  • Hodge G (2004) Disposable components enable a new approach to biopharmaceutical manufacturing. BioPharm Int 15:38–49

    Google Scholar 

  • Homma T, Fuji M, Mori J, Kawakami T, Kuroda K, Taniguchi M (1993) Production of cellobiose by enzymatic hydrolysis: removal of ß-glucosidase from cellulase by affinity precipitation using chitosan. Biotechnol Bioeng 41:405–410

    CAS  CrossRef  Google Scholar 

  • Hossler P, Khattak SF, Li ZJ (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19:936–949

    CAS  CrossRef  Google Scholar 

  • ICH (International Conference on Harmonization) Topic Q6B (1999a) Specifications: test procedures and acceptance criteria for biotechnology/biological products.

    Google Scholar 

  • ICH (International Conference on Harmonization) Topic Q5A (1999b) Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin

    Google Scholar 

  • ICH (International Conference on Harmonization) Topic Q8 (R2) (2009) Pharmaceutical development.

    Google Scholar 

  • ICH (International Conference on Harmonization) (2017) Guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk

    Google Scholar 

  • James AM (1992) Introduction fundamental techniques. In: James AM (ed) Analysis of amino acids and nucleic acids. Butterworth-Heinemann, Oxford, pp 1–28

    Google Scholar 

  • Jones N (2015) Single-Use Processing for Microbial Fermentations. BioProcess Int 13:56–62

    CrossRef  Google Scholar 

  • Kelley B (2009) Industrialization of mAb production technology. MAbs 1:443–452

    CrossRef  Google Scholar 

  • Klegerman ME, Groves MJ (1992) Pharmaceutical biotechnology. Interpharm Press, Buffalo Grove

    Google Scholar 

  • Krasnova L, Wong CH (2016) Understanding the chemistry and biology of glycosylation with glycan synthesis. Annu Rev Biochem 85:599–630

    CAS  CrossRef  Google Scholar 

  • Larsen B, Hwang J (2010) Mycoplasma, ureaplasma, and adverse pregnancy outcomes: a fresh look. Infect Dis Obstet Gynecol 2010:1–7

    Google Scholar 

  • Löwer J (1990) Risk of tumor induction in vivo by residual cellular DNA: quantitative considerations. J Med Virol 31:50–53

    CrossRef  Google Scholar 

  • Luitjens A, Lewis J, Pralong A (2012) Single-use biotechnologies and modular manufacturing environments invite paradigm shifts in bioprocess development and biopharmaceutical manufacturing. In: Subramanian G (ed) Biopharmaceutical production technology, vol 1&2. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 817–857

    CrossRef  Google Scholar 

  • Maerz H, Hahn SO, Maassen A, Meisel H, Roggenbuck D, Sato T, Tanzmann H, Emmrich F, Marx U (1996) Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration. Nat Biotechnol 14:651–652

    CAS  CrossRef  Google Scholar 

  • Marcus-Sekura CJ (1991) Validation and removal of human retroviruses. Center for Biologics Evaluation and Research, FDA, Bethesda

    Google Scholar 

  • Minor PD (1994) Ensuring safety and consistency in cell culture production processes: viral screening and inactivation. Trends Biotechnol 12:257–261

    CAS  CrossRef  Google Scholar 

  • Monteclaro F (2010) Protein expression systems, ringing in the new. Innov Pharm Technol 12:45–49

    Google Scholar 

  • Orzaez D, Granell A, Blazquez MA (2009) Manufacturing antibodies in the plant cell. Biotechnol J 4:1712–1724

    CAS  CrossRef  Google Scholar 

  • PDA (2005) PDA technical report no. 41: virus filtration. PDA J Pharm Sci Technol 59(S-2):1–42

    Google Scholar 

  • Peters J, Stoger E (2011) Transgenic crops for the production of recombinant vaccines and anti-microbial antibodies. Hum Vaccin 7:367–374

    CAS  CrossRef  Google Scholar 

  • Sharma SK (1990) Key issues in the purification and characterization of recombinant proteins for therapeutic use. Adv Drug Deliv Rev 4:87–111

    CAS  CrossRef  Google Scholar 

  • Shukla AA, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261

    CAS  CrossRef  Google Scholar 

  • Shukla AA, Wolfe LS, Mostafa SS, Norman C (2017) Evolving trends in mAb production processes. Bioeng Transl Med 2:58–69

    CrossRef  Google Scholar 

  • Sinclair A, Brower M, Lopes AG, Pollard D, Abe Y (2016) Standardized economic cost modeling for next-generation MAb production. BioProcess Int 14:14–23

    Google Scholar 

  • Sinclair AM, Elliott S (2005) Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94:1626–1635

    CAS  CrossRef  Google Scholar 

  • Tennikova T, Svec F (1993) High performance membrane chromatography: highly efficient separation method for proteins in ion-exchange, hydrophobic interaction and reversed phase modes. J Chromatogr 646:279–288

    CAS  CrossRef  Google Scholar 

  • Terstappen G, Ramelmeier R, Kula M (1993) Protein partitioning in detergent-based aqueous two-phase systems. J Biotechnol 28:263–275

    CAS  CrossRef  Google Scholar 

  • Turner R, Joseph A, Titchener-Hooker N, Bender J (2017) Manufacturing of proteins and antibodies: chapter downstream processing technologies, harvest operations. In: Advances biochemical engineering/biotechnology. Springer, Berlin

    Google Scholar 

  • Van Wezel AL, Van der Velden-de Groot CA, De Haan HH, Van den Heuvel N, Schasfoort R (1985) Large scale animal cell cultivation for production of cellular biologicals. Dev Biol Stand 60:229–236

    PubMed  Google Scholar 

  • Walsh C (2006) Posttranslational modification of proteins: expanding nature’s inventory, vol xxi. Roberts and Co. Publishers, Englewood, p 490

    Google Scholar 

  • Walter J, Werner RG (1993) Regulatory requirements and economic aspects in downstream processing of biotechnically engineered proteins for parenteral application as pharmaceuticals. In: Kroner KH, Papamichael N, Schütte H (eds) Downstream processing, recovery and purification of proteins, a handbook of principles and practice. Carl Hauser Verlag, Muenchen

    Google Scholar 

  • Walter J, Werz W, McGoff P, Werner RG, Berthold W (1991) Virus removal/inactivation in downstream processing. In: Spier RE, Griffiths JB, MacDonald C (eds) Animal cell technology: development, processes and products. Butterworth-Heinemann Ltd. Linacre House, Oxford, pp 624–634

    Google Scholar 

  • Walter K, Werz W, Berthold W (1992) Virus removal and inactivation, concept and data for process validation of downstream processing. Biotech Forum Eur 9:560–564

    CAS  Google Scholar 

  • Wheelwright SM (1993) Designing downstream processing for large scale protein purification. Biotechnology 5:789–793

    Google Scholar 

  • WHO (World Health Organization) (2010) Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Technical report series, proposed replacement of 878, annex 1. WHO, Geneva

    Google Scholar 

  • Yao J, Weng Y, Dickey A, Tressel KY (2015) Plants as factories for human pharmaceuticals: applications and challenges. Int J Mol Sci 16:28549–28565

    CAS  CrossRef  Google Scholar 

  • Zhou JX, Tressel T (2006) Basic concepts in Q membrane chromatography for large scale antibody production. Biotechnol Prog 22:341–349

    CAS  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emile van Corven .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Luitjens, A., van Corven, E. (2019). Production and Purification of Recombinant Proteins. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_4

Download citation